Ylberta Kajtazi1, Daniel Kaemmerer2, Jörg Sänger3, Stefan Schulz1, Amelie Lupp4. 1. Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Drackendorfer Str. 1, 07747, Jena, Germany. 2. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. 3. Laboratory of Pathology and Cytology Bad Berka, Bad Berka, Germany. 4. Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Drackendorfer Str. 1, 07747, Jena, Germany. Amelie.Lupp@med.uni-jena.de.
Abstract
PURPOSE: Pancreatic adenocarcinoma (PAC) represents one of the most fatal types of cancer with an exceptionally poor prognosis, underscoring the need for improved diagnostic and treatment approaches. An over-expression of somatostatin receptors (SST) as well as of the chemokine receptor CXCR4 has been shown for many tumour entities. Respective expression data for PAC, however, are scarce and contradictory. METHODS: Overall, 137 tumour samples from 70 patients, 26 of whom were diagnosed with PAC and 44 with pancreatic neuroendocrine tumour (PanNET), were compared in terms of SST and CXCR4 expression by immunohistochemical analysis using well-characterized rabbit monoclonal antibodies. RESULTS: Only SST1 and CXCR4 expression was detected in PAC tumours, with SST1 present in 42.3% and CXCR4 in 7.7% of cases. However, the overall staining intensity was very weak. In contrast to the tumour cells, in many PAC cases, tumour capillaries exhibited strong SST3, SST5, or CXCR4 expression. In PanNETs, SST2 was the most-prominently expressed receptor, observed in 75.0% of the tumours at medium-strong intensity. SST5, SST1, and CXCR4 expression was detected in 20.5%, 15.9%, and 11.4% of PanNET cases, respectively, but the staining intensity was only weak. SST2 positivity in PanNET, but not in PAC, was associated with favourable patient outcomes. CONCLUSIONS: SST or CXCR4 expression in PAC is clearly of no therapeutic relevance. However, indirect targeting of these tumours via SST3, SST5, or CXCR4 on tumour microvessels may represent a promising additional therapeutic strategy.
PURPOSE:Pancreatic adenocarcinoma (PAC) represents one of the most fatal types of cancer with an exceptionally poor prognosis, underscoring the need for improved diagnostic and treatment approaches. An over-expression of somatostatin receptors (SST) as well as of the chemokine receptor CXCR4 has been shown for many tumour entities. Respective expression data for PAC, however, are scarce and contradictory. METHODS: Overall, 137 tumour samples from 70 patients, 26 of whom were diagnosed with PAC and 44 with pancreatic neuroendocrine tumour (PanNET), were compared in terms of SST and CXCR4 expression by immunohistochemical analysis using well-characterized rabbit monoclonal antibodies. RESULTS: Only SST1 and CXCR4 expression was detected in PAC tumours, with SST1 present in 42.3% and CXCR4 in 7.7% of cases. However, the overall staining intensity was very weak. In contrast to the tumour cells, in many PAC cases, tumour capillaries exhibited strong SST3, SST5, or CXCR4 expression. In PanNETs, SST2 was the most-prominently expressed receptor, observed in 75.0% of the tumours at medium-strong intensity. SST5, SST1, and CXCR4 expression was detected in 20.5%, 15.9%, and 11.4% of PanNET cases, respectively, but the staining intensity was only weak. SST2 positivity in PanNET, but not in PAC, was associated with favourable patient outcomes. CONCLUSIONS: SST or CXCR4 expression in PAC is clearly of no therapeutic relevance. However, indirect targeting of these tumours via SST3, SST5, or CXCR4 on tumour microvessels may represent a promising additional therapeutic strategy.
Authors: J B Bachet; R Maréchal; P Demetter; F Bonnetain; A Couvelard; M Svrcek; A Bardier-Dupas; P Hammel; A Sauvanet; C Louvet; F Paye; P Rougier; C Penna; J C Vaillant; T André; J Closset; I Salmon; J F Emile; J L Van Laethem Journal: Ann Oncol Date: 2012-02-29 Impact factor: 32.976
Authors: L Buscail; N Saint-Laurent; E Chastre; J C Vaillant; C Gespach; G Capella; H Kalthoff; F Lluis; N Vaysse; C Susini Journal: Cancer Res Date: 1996-04-15 Impact factor: 12.701
Authors: Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp Journal: BMC Cancer Date: 2022-07-07 Impact factor: 4.638
Authors: Oana Popa; Sorina Maria Tăban; Alis Liliana Carmen Dema; Andrei Dorel Plopeanu; Robert Alexandru Barna; Mărioara Cornianu; Sorin Dema Journal: Rom J Morphol Embryol Date: 2021 Jan-Mar Impact factor: 1.033
Authors: Claudia Campana; Peter M van Koetsveld; Richard A Feelders; Wouter W de Herder; Anand M Iyer; Marie-Louise F van Velthuysen; Marije J Veenstra; Elisabeth S R van den Dungen; Sanne E Franck; Diego Ferone; Federico Gatto; Leo J Hofland Journal: Eur J Endocrinol Date: 2022-07-21 Impact factor: 6.558
Authors: Rosalba Mansi; Guillaume Pierre Nicolas; Luigi Del Pozzo; Karim Alexandre Abid; Eric Grouzmann; Melpomeni Fani Journal: Molecules Date: 2020-09-11 Impact factor: 4.411